List of Excipients in API ERDAFITINIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ERDAFITINIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Janssen Products LP | BALVERSA | erdafitinib | 59676-030 | CELLULOSE, MICROCRYSTALLINE | 2036-02-09 |
| Janssen Products LP | BALVERSA | erdafitinib | 59676-030 | CROSCARMELLOSE SODIUM | 2036-02-09 |
| Janssen Products LP | BALVERSA | erdafitinib | 59676-030 | FERRIC OXIDE YELLOW | 2036-02-09 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ERDAFITINIB
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ERDAFITINIB drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
ERDAFITINIB drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
ERDAFITINIB drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL MONOCAPRYLOCAPRATE
ERDAFITINIB drug variants containing GLYCERYL MONOCAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing GLYCERYL MONOCAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ERDAFITINIB drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
ERDAFITINIB drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MEGLUMINE
ERDAFITINIB drug variants containing MEGLUMINE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing MEGLUMINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
ERDAFITINIB drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
ERDAFITINIB drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
ERDAFITINIB drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ERDAFITINIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | erdafitinib | 59676-030 |
| >Company | >Ingredient | >NDC |
ERDAFITINIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
